Ontology highlight
ABSTRACT:
SUBMITTER: Olivier T
PROVIDER: S-EPMC9256830 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature
Olivier Timothée T Prasad Vinay V
Translational oncology 20220701
In 2021, the US Food and Drug Administration (FDA) approved two drugs targeting exon 20 directly: amivantamab and mobocertinib, under the accelerated approval pathway, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Here we discuss questions regarding the core question of an "unmet need" within the accelerated ap ...[more]